Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on January 16, 2012, detailing significant financing activities related to its pending acquisition of Pharmasset, Inc. The company entered into three new credit agreements totaling $3.00 billion: a $1.25 billion 5-year revolving credit facility, a $750 million short-term revolving credit facility, and a $1 billion term loan facility. These facilities are primarily intended to fund the Pharmasset acquisition, refinance existing debt, and cover related fees and general corporate purposes. Notably, Gilead borrowed $750 million under the 5-year facility and $400 million under the short-term facility on the closing date, with the full $1 billion term loan also drawn at that time, indicating immediate funding needs for the acquisition. In conjunction with these new credit facilities, Gilead Sciences also terminated its previous $1.25 billion Five-Year Revolving Credit Agreement dated December 18, 2007, fully prepaying outstanding obligations. This move signifies a restructuring of Gilead's debt and credit arrangements to support its strategic growth initiatives, particularly the acquisition of Pharmasset, which was a significant transaction for the company at the time. The new credit facilities provide substantial liquidity to execute this acquisition and manage ongoing operational needs.
Key Highlights
- 1Gilead Sciences entered into new credit facilities totaling $3.00 billion to finance the acquisition of Pharmasset, Inc.
- 2The new financing includes a $1.25 billion 5-year revolving credit facility, a $750 million short-term revolving credit facility, and a $1 billion term loan facility.
- 3On the closing date, Gilead borrowed $750 million under the 5-year revolving credit facility and $400 million under the short-term revolving credit facility.
- 4The full $1 billion term loan was also borrowed on the closing date, directly funding the Pharmasset acquisition and related expenses.
- 5Gilead Sciences terminated its previous $1.25 billion Five-Year Revolving Credit Agreement dated December 18, 2007.
- 6The credit agreements include provisions for revolving credit loans, swing line loans, and letter of credit sub-facilities.
- 7Proceeds from these facilities are earmarked for the Pharmasset acquisition, refinancing existing debt, and general corporate purposes.